Activating (also known as sensitising) mutations somatic EGFR mutations are present in 15–25% of Caucasian subjects and in 35–50% of East-Asian patients with untreated NSCLC [30,31,32]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.